Financial Movers: National Bank of Greece (NYSE:NBG), Freddie Mac (OTCBB:FMCC), Camtek (NASDAQ:CAMT), Rosetta Genomic (NASDAQ:ROSG)

Shares of National Bank of Greece (NYSE:NBG) are up nearly 10% Monday following Deutsche Bank’s new coverage of the stock at a Buy rating and EUR4.50 price target (approx $6.25 based on Monday’s exchange rate). The rating results from Deutsche Bank’s forecast for a strong recovery in fundamentals for the Greek banking sector. In addition, the bank will release Q4 earnings on March 27. It is expected to report a loss of $0.20 per share for 2013 versus a loss of $27.19 for 2012. National Bank of Greece (NYSE:NBG) last traded above its 200-day moving average of $5.02, with a 52-week range of $2.85 to $24.70.

Freddie Mac (OTCBB:FMCC) said it would offer $1.15 billion in new multifamily mortgage-backed securities (MBS), its third K Certificates offering so far in 2014. The offering of Structured Pass-Through Certificates are expected to price this week and settle on or about March 25. Freddie Mac (OTCBB:FMCC), a quasi-public guarantor of residential mortgages and investor in mortgages and related securities, was up at mid-day 3.5% to $5.33, not far from its 52-week high of $5.58. The offering is being headed by a syndicate of dealers led by Wells Fargo Securities, LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated as co-lead managers and joint book runners.

Semiconductor firm Camtek (NASDAQ:CAMT) said it started customer evaluation of its next-generation chip inspection and metrology platform, and shares climbed 3%. Camtek (NASDAQ:CAMT) called the development a “major milestone event” for rejuvenating its chip product line, and said it the new platform included 2D and 3D inspection capabilities. In afternoon trading,Camtek (NASDAQ:CAMT)  was up 3.47% to $3.88.

Rosetta Genomic (NASDAQ:ROSG) continues its meteoric rise again on Monday, up another 20% to a 17-month high of $6.48. The stock continues to gain traction from a bullish Seeking Alpha article from Friday. According to Seeking Alpha biotech analyst Grant Zeng, Rosetta Genomics (NASDAQ:ROSG) could reach $125 million in revenue by 2020, a 4,300% increase from projected 2014 revenue. In addition, at $6.30, the stock is undervalued by as much as 67%. Rosetta Genomics (NASDAQ:ROSG) develops microRNA-based diagnostics focused on molecular testing of cancer and other diseases. It currently markets four cancer tests including a test for lung and kidney cancer. The stock last traded at $6.24 with a new 52-week range of $2.35 to $6.48.




Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone